Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for form 1449B/PTO				Complete if Known			
					Application Number	10/087,987	,987	
	INFORMATION DISCLOSURE				Filing Date	03/05/2002		
	STATEMENT BY APPLICANT			CANT	First Named Inventor	ROBERT B DICKSON		
					Art Unit	1642		
	(Use as many sheets as necessary)				Examiner Name	Susan UNGAR		
	Sheet	1	of	2	Attorney Docket Number	082137-0280712		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		LONG ET AL., "Synthesis and evaluation o the sunflower derived trypsin inhibitor as a potent inhibitor of the type II transmembrane serine protease, matriptase," Bioorg. Med. Chem. Lett., Abstract, p. 2515-9, (September 17, 2001).			
	ACCOUNTS AND ACCOU	YAMASAKI ET AL., "Inhibition of membrane-type serine protease 1/matriptase by natural and synthetic protease inhibitors," J. Ntru Sci. Vitaminol., Abstract, Vol. 49 (No. 1), p. 27-32, (February 5, 2003).			
		STTOP ET AL., "Engineering of a macromolecular scaffold to develop specific protease inhibitors," Nat. Biotechnol., Vol. 21 ( No. 9), p. 1603-8, (September 5, 2003).			
		FORBS ET AL., "In vitro inhibition of matriptase preents invasive growth of cell lines of prostate and colon carcinoma," Int. J. Oncol., Vol. 27 (No. 4), p. 1061-70, (October 5, 2005).			
	***************************************	DESILETS ET AL., "Inhibition of human natriptase by eglin c variants," FEBS Lett., Vol. 580 (No. 9), p. 2227-32, (April 17, 2006).			
		GALKIN ET AL., "CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts," Vol. 61 (No. 3), p. 228-35, (November 1, 2004).			
	***********	FOLTZ ET AL., "Generation of a Fully Human High Affinity Neutrliazing Antibody Against MT-SP1/Matriptase and Its Potential Role for the Treatment of B Cell Lymphoma," Blood, Abstract, (June 5, 2005).			
		JANC ET AL., "A novel approach to serine protease inhibition: kinetic characterization of inhibitors whose potencies and selectivitie are dramatically are dramatically enhanced by Zinc (II)," Biochemistry, Abstract, Vol. 39 (No. 16), p. 4792-800, (April 25, 2000).			
	***************************************	KATZ ET AL., "Design of potent selective zinc-mediated serine protease inhibitors," Nature, Abstract, p. 608-12, (February 5, 1998).			
		LIST ET AL., "Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation," Genes & Development, Cold Spring Harbor Laboratory Press, p. 1934-50, (January 24, 2005).			

•			
1			
1	Examiner	Date	
l	Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449B/PTO Application Number 10/087,987 Filing Date INFORMATION DISCLOSURE 03/05/2002 STATEMENT BY APPLICANT First Named Inventor ROBERT B DICKSON Art Unit 1642 Examiner Name (Use as many sheets as necessary) Susan UNGAR Attorney Docket Number 2 082137-0280712 Sheet 2

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials* Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, and/or country where published.			T <sup>2</sup>		
	See Attachm 1	ent	er. John Kero		
************************	**>********	KANG ET AL., "Tissue Microarray Analysis of Hepatocyte Growth Factor/Met Pathway Components Reveals a Role for Met, Matriptase, and Hepatocyte Growth Factor Activator 1 in the Progression of Node-negative Breast Cancer," Cancer Research, p. 1101-05, (March 1, 2003).  Envedored at all "Structure-based approach for the discovery of bis-benzamidines	********		
***************************************	************	Enyedy et al. "Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase; J. Med. Chem. pp. 1349-55 (Abstract) April 26, 2001	**********		
44,14(43)]KKA45(ESICPASFS)	***************************************				
		-			
***************************************	,49,111,941,4463,989		**********		
***************************************					
		Date	$\overline{}$		

Examiner	Date	
Signature	Considered	
	· · · · · · · · · · · · · · · · · · ·	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## Addendum

## Attachment 1

a.

b. SUZUKI ET AL., "Inhibition of Tumor Invasion by Genomic Down-regulation of Matriptase through Suppression of Activation of Receptor-bound Pro-urokinase," J. of Biol. Chem., The American Society for Biochemistry and Molecular Biology, Inc., Vol. 279 (No. 15), p. 14899-908, (April 9, 2004).

c.